

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Blas José Gómez-Rodríguez

UEG Week Copenhagen 2023

Poster

Stomach & H. Pylori

October 15, 2023

A European registry study of 8,302 patients found that 10-day single-capsule bismuth-quadruple therapy achieved approximately 90% H. pylori eradication in real-world practice as both first-line and rescue treatment.

KEY POINTS

- Overall eradication rates were 91.5% by modified intention-to-treat and 92% by per-protocol analysis across all treatment lines.
- First-line therapy achieved the highest effectiveness at 93% (mITT), while second-line achieved 87% and third-to-sixth-line rescue therapy achieved 86%.
- Compliance with treatment (greater than 90% of drug intake) was reported in 93% of cases and was the factor most closely associated with treatment effectiveness.
- Adverse events occurred in 26% of patients but were generally mild-to-moderate and transient, with only 0.1% reporting serious adverse events and 1.7% discontinuing treatment.
- Gastroenterologists managing H. pylori infection in treatment-naïve or treatment-experienced patients would benefit from these real-world effectiveness and safety data.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/9a951048-743b-11ee-815d-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.